First Time Loading...

Alphamab Oncology
HKEX:9966

Watchlist Manager
Alphamab Oncology Logo
Alphamab Oncology
HKEX:9966
Watchlist
Price: 5.19 HKD -0.76% Market Closed
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Alphamab Oncology

Wall Street analysts forecast Alphamab Oncology stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Alphamab Oncology is 8.38 HKD with a low forecast of 3.64 HKD and a high forecast of 21 HKD.

Lowest Forecast
Wall Street Target
3.64 HKD
30% Downside
Average Forecast
Wall Street Target
8.38 HKD
62% Upside
Highest Forecast
Wall Street Target
21 HKD
305% Upside
Lowest
Price Target
3.64 HKD
30% Downside
Average
Price Target
8.38 HKD
62% Upside
Highest
Price Target
21 HKD
305% Upside
Alphamab Oncology Competitors:
Price Targets
S
SABS
SAB Biotherapeutics Inc
292% Upside
UTHR
United Therapeutics Corp
15% Upside
NIOX
Niox Group PLC
10% Upside
ZYME
Zymeworks Inc
76% Upside
S
SABS
SAB Biotherapeutics Inc
292% Upside
UTHR
United Therapeutics Corp
15% Upside
NIOX
Niox Group PLC
10% Upside
ZYME
Zymeworks Inc
76% Upside
N
688105
Nanjing Vazyme Biotech Co Ltd
56% Upside
IONS
Ionis Pharmaceuticals Inc
35% Upside
ARQT
Arcutis Biotherapeutics Inc
130% Upside
ACHV
Achieve Life Sciences Inc
325% Upside

Revenue
Forecast

Revenue Estimate
Alphamab Oncology

The compound annual growth rate of Alphamab Oncology's revenue for the next 3 years is 39%.

N/A
Past Growth
39%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Alphamab Oncology

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-32%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Alphamab Oncology

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Alphamab Oncology's stock price target?
Price Target
8.38 HKD

According to Wall Street analysts, the average 1-year price target for Alphamab Oncology is 8.38 HKD with a low forecast of 3.64 HKD and a high forecast of 21 HKD.

What is Alphamab Oncology's Revenue forecast?
Projected CAGR
39%

The compound annual growth rate of Alphamab Oncology's revenue for the next 3 years is 39%.

ALPHA SPREAD
Join more than 134,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.